Post

Satellos reported that the FDA and other global regulators have cleared its IND for SAT-3247, enabling a three-month Phase 2, placebo-controlled trial in 51 ambulatory children with Duchenne muscular dystrophy. #satellos #dmd #duchenne 👉 Read More: DMDWarrioR.com